Overactive bladder syndrome: Management and treatment options

Hutchinson, A.; Nesbitt, Alexander L; Joshi, Andre; Clubb, Adrian; Perera, Marlon

doi:10.31128/ajgp-11-19-5142

Cited by 23 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 In cases with good compliance, the success rate of nonselective agents is approximated at 65%. 8 Botulinum toxin injected in the detrusor is a secondline treatment with good efficacy. When studied on neurological population alone, it improved voided volume, bladder pressure, urodynamic parameters, and quality of life.…”

Section: Discussionmentioning

confidence: 99%

Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity

Ciofu¹,

Ceaușu²,

Chirca³

et al. 2022

American Journal of Therapeutics

View full text Add to dashboard Cite

Background:Neurogenic detrusor overactivity (NDO) is treated with antimuscarinics as first-line treatment. For patients with contraindications or unresponsive, intradetrusor injections with botulinum toxin (BoNT) are a safe and effective but expensive option.Study Question:Our study evaluated whether adding solifenacin to the intradetrusor injection of BoNT A could boost the effect of BoNT in patients with NDO due to multiple sclerosis or spinal cord injury refractory to antimuscarinics alone and/or lead to less frequent injections.Study Design:We performed a prospective study on 49 patients assigned alternatively to group A, undergoing BoNT injections, and group B, adding solifenacin.Measures and Outcomes:We gathered data from urodynamic testing and questionnaire assessments before and 3 months after injections and reinjections. We analyzed 39 patients who achieved total continence and a minimum 24-month follow-up period.Results:After treatment, both groups had statistically significant improvement of overactive bladder questionnaire (OABq) score, post void residue (PVR), and peak detrusor pressure (Pdet). Reinjection was needed after a mean 8.2 months for group A and 11.7 months for group B. We analyzed the improvement rate of parameters compared between the 2 groups—group B had greater OABq score improvement (A = 17.25 ± 5.07, B = 20.44 ± 4.51, P = 0.0485), as well as for maximum bladder capacity (A = 11.05 ± 7.04 mL, B = 19.39 ± 6.43 mL, P = 0.0005); differences in Pdet change (A = 51.72 ± 16.57 cmH2O, B = 50.80 ± 16.33 cmH2O, P = 0.7635) and PVR change (A = 17.67 ± 12.63 mL, B = 12.30 ± 8.32 mL, P = 0.126) were not statistically significant.Conclusions:Our study shows that adding solifenacin improves patient satisfaction, increases the interval between reinjections, thus lowering costs, and improves maximum bladder capacity. Pdet was kept in safe ranges, but no statistically significant conclusions could be drawn regarding Pdet and PVR decrease related to adding solifenacin. Although our study is limited by the small series of patients and lack of randomization and placebo control group, the BoNT–solifenacin combination could be considered in NDO in terms of cost-effectiveness. Further studies would be beneficial.

show abstract

Section: Discussionmentioning

confidence: 99%

Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity

Ciofu¹,

Ceaușu²,

Chirca³

et al. 2022

American Journal of Therapeutics

View full text Add to dashboard Cite

show abstract

“…OAB syndrome is characterized by the urgency of urination. Its clinical manifestations include frequent urination and nocturia with or without urinary incontinence and without urinary tract infections or other definite lesions (1)(2)(3). Relevant studies showed that OAB was a highly prevalent disease worldwide with a 17% incidence rate (4).…”

Section: Introductionmentioning

confidence: 99%

Comprehensive analysis of global research on overactive bladder: A scientometric approach

et al. 2023

View full text Add to dashboard Cite

BackgroundOveractive bladder, a syndrome marked by an urgent need to urinate, is a globally prevalent ailment. Human health and quality of life are seriously affected. Therefore, it is essential to investigate the current progress and trends in this field.ObjectiveNo bibliometric analysis of overactive bladder has been conducted. Through the use of bibliometrics and visualization, this study intends to examine the current progress and development trend of this field.MethodsGlobal publications on overactive bladder between January 2004 and August 2022 were extracted from the Web of Science core collection database. A bibliometric and visual analysis was carried out using VOSviewer software and CiteSpace.ResultsOver the last 20 years, publications have grown rapidly, but after 2019, they started to fall. According to the collaboration network, the United States, Univ Pittsburgh AND NEUROUROLOGY AND URODYNAMICS are the most active countries, institutes AND journals in the field, respectively. All keywords were categorized by the symbiosis analysis into four categories: experimental study, symptoms, clinical use, and quality of life. The most prevalent keyword across all clusters is “overactive bladder.”ConclusionYear after year, there have been more publications in the field of overactive bladder research in many countries, and there has been a deeper level of cooperation and exchange. Researchers will still be interested in overactive bladder in the future. Currently, the clinical application of the disease and the safety and effectiveness of medications are being investigated. However, radical innovation in relevant experimental technologies is a significant obstacle in this field.

show abstract

“…Those ailments may considerably deteriorate the quality of life and cause various social, work-related, psychological and sexual problems [2]. Research conducted in Europe and the United States showed that the manifestations of OAB were present in more than 10% of the general population, with the risk double in persons > 65 years of age [3]. The results of another epidemiological study suggest that the symptoms of OAB may occur in up to 16% of persons aged 40 years or older [4].…”

Section: Introductionmentioning

confidence: 99%

Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report

2022

View full text Add to dashboard Cite

show abstract

Overactive bladder syndrome: Management and treatment options

Cited by 23 publications

References 19 publications

Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity

Solifenacin Treatment After Intradetrusor Injections With Botulinum Toxin in Patients With Neurogenic Detrusor Overactivity

Comprehensive analysis of global research on overactive bladder: A scientometric approach

Quality of life in patients with overactive bladder following botulinum toxin treatment: a preliminary report

Contact Info

Product

Resources

About